<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869479</url>
  </required_header>
  <id_info>
    <org_study_id>2008P002371</org_study_id>
    <nct_id>NCT00869479</nct_id>
  </id_info>
  <brief_title>Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis</brief_title>
  <official_title>Validation of a Questionnaire as a Screening Tool to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary Aim of this study is to validate a questionnaire as a screening tool to identify
      subjects with symptoms suggestive of nephrogenic systemic fibrosis (NSF). The investigators
      believe that there will be difference between subjects with NSF and other skin conditions and
      normal skin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the number of &quot;yes&quot; answers between NSF subjects and subjects with non-fibrosing skin diseases or without skin diseases.</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Similarity in answers between NSF subjects and subjects with other fibrosing skin diseases.</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of the questionnaire when applied to NSF subjects.</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nephrogenic Systemic Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>subjects with a histologically-proven diagnosis of NSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>subjects with other fibrosing skin diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>subjects with non-fibrosing skin diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>subjects without skin diseases</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Massachusetts General Hospital Dermatology and Rheumatology clinics
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects 18 years of age or older.

          2. Willing and able to understand and provide oral informed consent.

          3. Able to complete study and comply with study procedures.

        Exclusion Criteria:

          1. Subject is unable to provide oral consent.

          2. Psychiatric or other conditions which might, in the opinion of the Principal
             Investigator, interfere with study evaluations or pose a risk to subject safety during
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Kay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Todd DJ, Kay J. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep. 2008 Jul;10(3):195-204. Review.</citation>
    <PMID>18638427</PMID>
  </reference>
  <reference>
    <citation>Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007 Oct;56(10):3433-41.</citation>
    <PMID>17907148</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <last_update_submitted>December 14, 2010</last_update_submitted>
  <last_update_submitted_qc>December 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alexandra Kimball, MD</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <keyword>Nephrogenic Systemic Fibrosis</keyword>
  <keyword>Screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
    <mesh_term>Nephrogenic Fibrosing Dermopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

